A Pilot Study About the Safety and Efficacy of Intra-articular Bevacizumab (Avastin) for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Haemophilia A; Haemophilia B; Haemophilic arthropathy; Synovitis
- Focus Therapeutic Use
- 22 Feb 2019 Planned End Date changed from 1 Jun 2016 to 31 Dec 2020.
- 22 Feb 2019 Planned primary completion date changed from 1 Dec 2015 to 31 Dec 2019.
- 31 Aug 2018 Biomarkers information updated